William H Meyer
Overview
Explore the profile of William H Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen-Rhoades W, Lupo P, Scheurer M, Chi Y, Kuttesch J, Venkatramani R, et al.
Cancer Med
. 2023 Apr;
12(9):10222-10229.
PMID: 37016270
Background: Patients with alveolar rhabdomyosarcoma (ARMS) have inferior outcomes compared to patients with embryonal rhabdomyosarcoma (ERMS) and more effective chemotherapy options are needed for these patients. Vinorelbine is a semisynthetic...
2.
Sparber-Sauer M, Ferrari A, Spunt S, Vokuhl C, Casey D, Lautz T, et al.
Cancer Med
. 2023 Feb;
12(10):11719-11730.
PMID: 36744538
Background: Margin status following surgery in children, adolescents, and young adults with soft tissue sarcomas is controversial and has been defined differently by various specialties, with definitions changing over time...
3.
Ferrari A, Orbach D, Sparber-Sauer M, Walterhouse D, Pajtler K, Meyer W, et al.
Eur J Cancer
. 2022 May;
169:10-19.
PMID: 35490564
The current article focuses on non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), the heterogeneous group of mesenchymal tumours different from rhabdomyosarcoma that may affect children and adolescents, with clinical behaviour varying from...
4.
Crane J, Xue W, Qumseya A, Gao Z, Arndt C, Donaldson S, et al.
Pediatr Blood Cancer
. 2022 Mar;
69(6):e29644.
PMID: 35253352
The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after...
5.
Ferrari A, Spunt S, Sparber-Sauer M, Walterhouse D, Pajtler K, Meyer W, et al.
Lancet Child Adolesc Health
. 2022 Feb;
6(4):221-223.
PMID: 35176224
No abstract available.
6.
Ilonze C, Galipp K, Scordino T, Meyer W, Baker A
J Pediatr Hematol Oncol
. 2021 Jul;
43(8):e1115-e1117.
PMID: 34224518
Cyclic neutropenia has been rarely associated with chronic inflammation and development of reactive AA amyloidosis. We report a family with cyclic neutropenia with associated renal and thyroid amyloid. A 12-year-old...
7.
Pacenta H, Allen-Rhoades W, Langenau D, Houghton P, Keller C, Heske C, et al.
J Clin Med
. 2021 Apr;
10(7).
PMID: 33915882
Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children's Oncology Group...
8.
Harrison D, Chi Y, Tian J, Hingorani P, Mascarenhas L, McCowage G, et al.
Cancer Med
. 2020 Dec;
10(3):857-866.
PMID: 33340280
Background: Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification to assign therapy aiming to minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic...
9.
Weiss A, Chen Y, Scharschmidt T, Chi Y, Tian J, Black J, et al.
Lancet Oncol
. 2020 Jul;
21(8):1110-1122.
PMID: 32702309
Background: Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near...
10.